Results 71 to 80 of about 38,450 (306)
Chemical generation of bispecific antibodies
, 2010 Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability ...
Lingna Li +21 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis +5 more
wiley +1 more source
mAbsThe Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics.
Silvia Crescioli +6 more
doaj +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Bispecific antibodies targeting human CD73
, 2017 The present invention relates to a bispecific antibody targeting CD73. In particular, the present invention relates to a bispecific antibody targeting different epitopes on CD73 or a bispecific antibody targeting an epitope on CD73 and an epitope on a ...
Gammelgaard, Odd Lilleng, Ditzel, Henrik
core +1 more source
Frontiers in ImmunologyBackgroundAt the time of diagnosis, 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are already at an unresectable advanced stage. The median overall survival (mOS) with traditional AG chemotherapy is only 8.5 months. The bispecific antibody
Wenke Qin +12 more
doaj +1 more source
Bispecific antibodies: design, therapy, perspectives
, 2018 Sergey E Sedykh, Victor V Prinz, Valentina N Buneva, Georgy A Nevinsky Laboratory of Repair Enzymes, Siberian Branch of Russian Academy of Sciences Institute of Chemical Biology and Fundamental Medicine, Novosibirsk State University, Novosibirsk, Russia
Buneva VN +3 more
core
Inhibition assays for bispecific antibody.
, 2013 To determine the specificity of bispecific antibody, unlabeled digoxin (0, 1, 10, 100 ng/mL) or DNP (0, 1, 10, 100 µg/mL) were used as competitors with the HRP-labeled haptens in bispecific antibody ELISAs and the decreased antibody titers were plotted.
Jinming Li (128865) +2 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan +11 more
wiley +1 more source
Frontiers in Bioengineering and BiotechnologyIntroductionCodon optimization is utilized in biologics design to maximize protein expression. Selecting the host organism’s most frequently used codons for each amino acid can significantly enhance recombinant protein expression yields.
Timothy Z. Chang +10 more
doaj +1 more source